Dexrazoxane

CHEMBL1738 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
268.3 g/mol
LogP
-1.4
Phase
4

A cardioprotective agent and bisdioxopiperazine prodrug that is hydrolyzed to an EDTA-like compound that chelates intracellular iron, reducing anthracycline-induced cardiac toxicity in cancer patients receiving high cumulative doxorubicin doses. It is also used to treat extravasation injury from anthracycline chemotherapy.

น้ำหนักโมเลกุล

268.2700 g/mol

LogP

-1.40

TPSA

98.80 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1

InChI

InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1

Molecular Formula

C11H16N4O4

HBD / HBA

2 / 6

พันธะที่หมุนได้

3

อะตอมหนัก

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A cardioprotective agent and bisdioxopiperazine prodrug that is hydrolyzed to an EDTA-like compound that chelates intracellular iron, reducing anthracycline-induced cardiac toxicity in cancer patients receiving high cumulative doxorubicin doses. It is also used to treat extravasation injury from anthracycline chemotherapy.

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Yes, Dexrazoxane is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1738. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71384. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.